GB2337520B - Delivery system - Google Patents

Delivery system

Info

Publication number
GB2337520B
GB2337520B GB9811153A GB9811153A GB2337520B GB 2337520 B GB2337520 B GB 2337520B GB 9811153 A GB9811153 A GB 9811153A GB 9811153 A GB9811153 A GB 9811153A GB 2337520 B GB2337520 B GB 2337520B
Authority
GB
United Kingdom
Prior art keywords
delivery system
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB9811153A
Other versions
GB2337520A (en
GB9811153D0 (en
Inventor
Alan John Kingsman
Susan Mary Kingsman
Fiona Margaret Ellard
Kyriacos Andreou Mitraphanous
Deva Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Priority to GB9811153A priority Critical patent/GB2337520B/en
Publication of GB9811153D0 publication Critical patent/GB9811153D0/en
Priority to AU39473/99A priority patent/AU763007B2/en
Priority to CA002328491A priority patent/CA2328491A1/en
Priority to AT99922378T priority patent/ATE435297T1/en
Priority to EP99922378A priority patent/EP1080216B1/en
Priority to US09/701,014 priority patent/US6818209B1/en
Priority to DE69941049T priority patent/DE69941049D1/en
Priority to JP2000551022A priority patent/JP4612950B2/en
Priority to CNB998065005A priority patent/CN1325653C/en
Priority to KR1020007011917A priority patent/KR20010074493A/en
Priority to GB0024915A priority patent/GB2351290A/en
Priority to PCT/GB1999/001607 priority patent/WO1999061639A2/en
Publication of GB2337520A publication Critical patent/GB2337520A/en
Application granted granted Critical
Publication of GB2337520B publication Critical patent/GB2337520B/en
Priority to US10/918,905 priority patent/US20060099180A1/en
Priority to US11/583,427 priority patent/US20070213290A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15061—Methods of inactivation or attenuation
    • C12N2740/15062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
GB9811153A 1996-10-17 1998-05-22 Delivery system Expired - Fee Related GB2337520B (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GB9811153A GB2337520B (en) 1998-05-22 1998-05-22 Delivery system
CNB998065005A CN1325653C (en) 1998-05-22 1999-05-21 Retroviral delivery system
GB0024915A GB2351290A (en) 1998-05-22 1999-05-21 Retroviral delivery sytem
AT99922378T ATE435297T1 (en) 1998-05-22 1999-05-21 RETROVIRAL ADMINISTRATION SYSTEM
EP99922378A EP1080216B1 (en) 1998-05-22 1999-05-21 Retroviral delivery system
US09/701,014 US6818209B1 (en) 1998-05-22 1999-05-21 Retroviral delivery system
DE69941049T DE69941049D1 (en) 1998-05-22 1999-05-21 RETROVIRAL ADMINISTRATION SYSTEM
JP2000551022A JP4612950B2 (en) 1998-05-22 1999-05-21 Retrovirus delivery system
AU39473/99A AU763007B2 (en) 1998-05-22 1999-05-21 Retroviral delivery system
KR1020007011917A KR20010074493A (en) 1998-05-22 1999-05-21 Retroviral delivery system
CA002328491A CA2328491A1 (en) 1998-05-22 1999-05-21 Retroviral delivery system
PCT/GB1999/001607 WO1999061639A2 (en) 1998-05-22 1999-05-21 Retroviral delivery system
US10/918,905 US20060099180A1 (en) 1998-05-22 2004-08-16 Retroviral delivery system
US11/583,427 US20070213290A1 (en) 1996-10-17 2006-10-19 Neurite regeneration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9811153A GB2337520B (en) 1998-05-22 1998-05-22 Delivery system

Publications (3)

Publication Number Publication Date
GB9811153D0 GB9811153D0 (en) 1998-07-22
GB2337520A GB2337520A (en) 1999-11-24
GB2337520B true GB2337520B (en) 2000-06-14

Family

ID=10832623

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9811153A Expired - Fee Related GB2337520B (en) 1996-10-17 1998-05-22 Delivery system

Country Status (1)

Country Link
GB (1) GB2337520B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0220467D0 (en) 2002-09-03 2002-10-09 Oxford Biomedica Ltd Composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) * 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
WO1996035454A1 (en) * 1995-05-08 1996-11-14 St. Jude Children's Research Hospital Stable virus packaging cell lines
WO1997024452A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Toxic-protein expressing viruses and producer cell lines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029440A1 (en) * 1993-06-04 1994-12-22 The Regents Of The University Of California Generation, concentration and efficient transfer of vsv-g pseudotyped retroviral vectors
WO1996035454A1 (en) * 1995-05-08 1996-11-14 St. Jude Children's Research Hospital Stable virus packaging cell lines
WO1997024452A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Toxic-protein expressing viruses and producer cell lines

Also Published As

Publication number Publication date
GB2337520A (en) 1999-11-24
GB9811153D0 (en) 1998-07-22

Similar Documents

Publication Publication Date Title
HUP0300246A3 (en) Delivery system
SG80049A1 (en) Delivery system
GB2345298B (en) Liquid delivery system
GB9816088D0 (en) System
GB2354323B (en) Location system
EP1221148A4 (en) Tactiovisual distance-to-exit exit-finding system
EP1061987A4 (en) Drug delivery system
PL348824A1 (en) Precompression system
HU9900470D0 (en) Condansation system
GB2334751B (en) Anti-pinching system
SG79983A1 (en) Conveying system
GB9721367D0 (en) Delivery system
GB9811691D0 (en) Flavour delivery systems
GB2352314B (en) Delivery system
GB0011066D0 (en) Delivery system
GB9816261D0 (en) Cross-care system
GB9907271D0 (en) System
GB9914960D0 (en) Delivery system
GB2343920B (en) Pumping System
GB9724786D0 (en) Oral delivery system
GB2341255B (en) Odering system
GB2375831B (en) Ranging system
GB2337520B (en) Delivery system
GB9911547D0 (en) Answerphone system
GB9811152D0 (en) Delivery system

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20140522